Cornea · 2026
Focal Subthreshold Laser Photocoagulation of Eyelid Margin Vascularity in Telangiectatic Meibomian Gland Dysfunction.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kappos Nikolaos, Georgalas Ilias, Papaconstantinou Dimitrios, Droutsas Konstantinos
Аннотация
PURPOSE: To evaluate the safety and efficacy of subthreshold micropulse laser photocoagulation for dry eye disease (DED) associated with telangiectatic meibomian gland dysfunction (MGD).
METHODS: In this prospective contralateral eye study, 60 eyes from 30 patients with DED secondary to MGD were randomized to receive either a single session of focal 532-nm subthreshold laser photocoagulation of eyelid margin telangiectasias (Laser Group, LG) or a sham treatment (Control Group, CG). Evaluations were performed at baseline and 2, 4, 8, and 12 weeks posttreatment and included Ocular Surface Disease Index (OSDI), tear break-up time (TBUT), Schirmer test, tear meniscus height and depth, eyelid margin vascularity, meibomian gland expressivity and secretion quality, ocular surface staining, meiboscore, and assessment of eyelid margin abnormalities. Best-corrected visual acuity (BCVA) and adverse events were recorded.
RESULTS: LG showed early and sustained improvements in tear film stability, tear meniscus parameters, and corneal staining from week 2 to week 12 (P < 0.05). No significant changes were observed in CG. Eyelid margin vascularity was significantly reduced until week 8 in LG (P < 0.001), with improvements in meibomian gland expressivity and secretion quality. Meiboscore and chronic eyelid margin structural features remained unchanged in both groups (P > 0.05). No ocular or systemic adverse events occurred, and BCVA remained stable throughout the follow-up period.
CONCLUSIONS: Focal subthreshold micropulse laser photocoagulation of eyelid margin telangiectasias appears to be a safe and effective adjunctive treatment for DED associated with MGD.
METHODS: In this prospective contralateral eye study, 60 eyes from 30 patients with DED secondary to MGD were randomized to receive either a single session of focal 532-nm subthreshold laser photocoagulation of eyelid margin telangiectasias (Laser Group, LG) or a sham treatment (Control Group, CG). Evaluations were performed at baseline and 2, 4, 8, and 12 weeks posttreatment and included Ocular Surface Disease Index (OSDI), tear break-up time (TBUT), Schirmer test, tear meniscus height and depth, eyelid margin vascularity, meibomian gland expressivity and secretion quality, ocular surface staining, meiboscore, and assessment of eyelid margin abnormalities. Best-corrected visual acuity (BCVA) and adverse events were recorded.
RESULTS: LG showed early and sustained improvements in tear film stability, tear meniscus parameters, and corneal staining from week 2 to week 12 (P < 0.05). No significant changes were observed in CG. Eyelid margin vascularity was significantly reduced until week 8 in LG (P < 0.001), with improvements in meibomian gland expressivity and secretion quality. Meiboscore and chronic eyelid margin structural features remained unchanged in both groups (P > 0.05). No ocular or systemic adverse events occurred, and BCVA remained stable throughout the follow-up period.
CONCLUSIONS: Focal subthreshold micropulse laser photocoagulation of eyelid margin telangiectasias appears to be a safe and effective adjunctive treatment for DED associated with MGD.